# Sensome

**Canonical:** https://apis.io/providers/sensome/  
**Website:** https://www.sensome.com/  
**APIs profiled:** 0

Sensome is a clinical-stage medical technology company developing tissue-sensing microchip technology and proprietary integration processes that embed real-time bio-impedance sensing into minimally invasive medical devices. Its lead product, the Clotild Smart Guidewire System (manufactured with Asahi Intecc), is the first tissue-sensing neurovascular guidewire, providing physicians real-time blood clot characterization to guide Acute Ischemic Stroke treatment; additional indications include lung cancer biopsy guidance. Surfaced as a portfolio company of Partech, Sensome is a medical-device hardware company with no public API, SDK, or developer platform at the time of enrichment.

## Kin Score — 6.5 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 6.5).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 7.1 |
| Commercial Clarity | 10.5 |
| Access Clarity | 10.5 |

Regulatory layer — **Health**: 5.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Healthcare, Medical Devices, MedTech, Sensors, Neurovascular, Bio-Impedance, Interventional Medicine

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/sensome/). Scores are computed from the provider's own public artifacts under a published rubric.